Abstract
ATR (Ataxia telangiectasia and Rad3-related kinase) ensures completion of DNA replication prior to mitosis and its inhibition is known to sensitize cancer cells to DNA damage. Excitingly, with the recent availability of potent, selective ATR inhibitors (ATRi), multiple studies indicate that ATR inhibition can potentiate anti-tumor immunity, largely through unknown mechanisms that may induce cGAS/STING/interferon. Here we explore if ATR inhibition could target Merkel cell carcinoma (MCC) which is immunogenic but often becomes refractory to PD-1 pathway blockade.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
